Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 106, Issue 8, Pages 2847-2852Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.0812890106
Keywords
[F-18] FAC; individualized chemotherapy; molecular imaging; deoxycytidine kinase
Categories
Funding
- NIH [P50 CA86306]
- National Cancer Institute/National Institutes of Health [5U54 CA119347, R24CA92865]
- U. S. Department of Energy [DE-FG02-06ER64249]
- Dana Foundation
- Merck Research Laboratories
Ask authors/readers for more resources
Gemcitabine (2',2'-difluorodeoxycytidine, dFdC) and cytosine arabinoside (cytarabine, ara-C) represent a class of nucleoside analogs used in cancer chemotherapy. Administered as prodrugs, dFdC and ara-C are transported across cell membranes and are converted to cytotoxic derivatives through consecutive phosphorylation steps catalyzed by endogenous nucleoside kinases. Deoxycytidine kinase (DCK) controls the rate-limiting step in the activation cascade of dFdC and ara-C. DCK activity varies significantly among individuals and across different tumor types and is a critical determinant of tumor responses to these prodrugs. Current assays to measure DCK expression and activity require biopsy samples and are prone to sampling errors. Noninvasive methods that can detect DCK activity in tumor lesions throughout the body could circumvent these limitations. Here, we demonstrate an approach to detecting DCK activity in vivo by using positron emission tomography (PET) and F-18-labeled 1-(2'-deoxy-2'-fluoroarabinofuranosyl) cytosine] ([F-18]FAC), a PET probe recently developed by our group. We show that [F-18]FAC is a DCK substrate with an affinity similar to that of dFdC. In vitro, accumulation of [F-18]FAC in murine and human leukemia cell lines is critically dependent on DCK activity and correlates with dFdC sensitivity. In mice, [F-18]FAC accumulates selectively in DCK-positive vs. DCK-negative tumors, and [F-18]FAC microPET scans can predict responses to dFdC. We suggest that [F-18]FAC PET might be useful for guiding treatment decisions in certain cancers by enabling individualized chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available